A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiati
This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
| Condition(s) | Chronic Rhinosinusitis With Nasal Polyps |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab. |
| Who can participate | Inclusion Criteria: * Age 1\. Participant must be 18 years of age or older, at the time of signing the informed consent. * Type of Participant and Disease Characteristics 2. Participants who are with physician-diagnosed CRSwNP for at least 12 months prior to Visit 1 who have all of the following: * Severity consistent with the need for surgery as defined by total NPS ≥ 4 (at least 2 for each nostril) at screening, as determined by the central reader * Mean NCS ≥ 2 in the 2 weeks prior to Visit 2 * Ongoing documented NP symptoms for \> 8 weeks prior to screening such as rhinorrhoea, reduction or loss of smell and/or poor quality/loss of sleep * SNOT-22 total score ≥ 30 as assessed at screening. 3. Any standard of care for treatment of CRSwNP, which must include treatment with intranasal cor |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | AstraZeneca |
| Locations | Beijing, China |
| Start date | 2026-04-24 |
| NCT ID | NCT07520162 |
| Official listing | https://clinicaltrials.gov/study/NCT07520162 |